(2) San Marco Veterinary Clinic, Veggiano, Padova, Italy.
Silvia Martínez-subiela (1)
Marco Caldin (2)
José Cerón (1)
Asta Tvarijonaviciute (1)
Adiponectin is an adipokine that exerts several actions, including regulation of carbohydrate and lipid metabolism and anti-diabetic, anti- inflammatory and anti-atherogenic properties. Its measurements could be of high interest for clinical evaluation and monitoring of obesity and endocrine diseases. However the lack of efficient and suitable assays limit the use of this biomarker in practice. In this report a new heterologous assay for adiponectin determination in serum and saliva of dogs which can detect with precision amounts of adiponectin and it is not interfered by lipemia was developed and validated. In addition changes in adiponectin serum and saliva of obese (n=7), overweight (n=8) and lean dogs (n=11) were studied.
The assay developed was able of measure adiponectin in serum and saliva of dogs with high repeatability and accuracy, and it is more sensitive and faster that the current assays available, in addition it is not affected by lipemia, which made this assay specially suitable for the evaluation of obese dogs and dogs with endocrine diseases that usually has lipemic serum. A significant increase of adiponectin concentrations was found in serum of obese dogs compared to lean dogs and although no significant changes in saliva were found between lean and obese dogs a correlation between serum and saliva were observed.
In conclusion, this new assay has major advantages compared with previous assays and can allow a wider and more accurate use of adiponectin measurement in dogs openings news perspectives in the studies of canine obesity and endocrine diseases.BIBLIOGRAFÍA
1. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986/02/08. 1986;1(8476):307–10.
2. Li G, Kawasumi K, Okada Y, Ishikawa S, Yamamoto I, Arai T, et al. Comparison of plasma lipoprotein profiles and malondialdehyde between hyperlipidemia dogs with/without treatment. BMC Vet Res. 2014;10(1):1–5.
3. Tvarijonaviciute A, Martinez-Subiela S, Ceron JJ. Validation of 2 commercially available enzyme-linked immunosorbent assays for adiponectin determination in canine serum samples. Can J Vet Res. 2011/01/05. 2010;74(4):279–85.
4. Tvarijonaviciute A, Carrillo-Sanchez JD, Garcia-Martinez JD, Tecles F, Martinez-Subiela S, German AJ, et al. Measurement of salivary adiponectin concentrations in dogs. Vet Clin Pathol. 2014;43(3):416–21.
5. Zhao H, Lin G, Liu T, Liang J, Ren Z, Liang R, et al. Rapid quantitation of human epididymis protein 4 in human serum by amplified luminescent proximity homogeneous immunoassay (AlphaLISA). J Immunol Methods [Internet]. 2016;437:64–9. Available from: http://dx.doi.org/10.1016/j.jim.2016.08.006
6. Chandran M, Phillips SA, Ciaraldi T, Henry RR. Adiponectin: more than just another fat cell hormone? Diabetes Care. 2003 Aug;26(8):2442–50.
7. Goodson JM, Kantarci A, Hartman M-L, Denis G V, Stephens D, Hasturk H, et al. Metabolic disease risk in children by salivary biomarker analysis. PLoS One [Internet]. 2014 [cited 2017 Nov 20];9(6):e98799. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24915044
8. Tvarijonaviciute A, Ceron JJ, Martinez-Subiela S, García-Martinez JD. Serum and urinary adiponectin in dogs with renal disease from leishmaniasis. Vet Rec. 2012;171(12):297.
